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Losartan reduces the burden and cost of ESRD: Public health The number of adults with diabetes worldwide will grow
implications from the RENAAL study for the European Union. from 135 million (1995) to 300 million (2025) [1]. In Europe
Type 2 diabetes is the leading cause of end-stage renal dis- there were an estimated 22.3 million people with diabetesease (ESRD) in most industrialized countries in Europe. The
of whom 94.9% of these have type 2 diabetes [2]. Type 2RENAAL (Reduction of Endpoints in NIDDM with the An-
giotensin II Antagonist Losartan) Study evaluated the renal diabetes is the leading cause of ESRD in Europe [3].
protective effects of losartan versus placebo on a background The contribution of diabetes, along with hypertension, to
of non-ACE-I/non-AIIA conventional antihypertensive ther- the incidence of ESRD has grown consistently through-apy in 1513 patients with type 2 diabetes and nephropathy. Lo-
out the 1980s and 1990s in Europe [4]. As the number ofsartan reduced the incidence of doubling of serum creatinine,
diabetics increases over time, it is likely that more pa-end-stage renal disease (ESRD), or death by 16% (P  0.022)
and reduced the risk of progression to ESRD, defined as the tients will require chronic dialysis or renal transplants.
initiation of dialysis or transplantation, by 29% (P  0.002). Expenditures on ESRD will increase as a consequence
We set out to estimate the potential effect of losartan on the
and facilities delivering healthcare for end-stage renalburden and costs associated with ESRD over 3.5 years in the
disease will be overburdened. In the US, as an example,European Union (EU). The risk reduction in new cases of ESRD
was calculated by combining type 2 diabetes population esti- ESRD costs are projected to more than double from
mates for the EU with the percent absolute risk reduction of $11.8 billion (1998) to $28.3 billion (2010) [5].
ESRD in patients treated with losartan as observed in RENAAL.
The design and results of the RENAAL Study haveThe number of days each patient experienced ESRD was de-
been previously reported [6]. The RENAAL (Reduc-fined as the length of time from onset of ESRD until the mini-
mum of death or 3.5 years. ESRD-free person-years avoided tion of Endpoints in NIDDM with the Angiotensin II
with losartan treatment were calculated by combining the pop- Antagonist Losartan) Study evaluated the renal protec-
ulation estimate with the ESRD days avoided divided by num-
tive effects of losartan versus placebo on a backgroundber of days in a year. ESRD costs from Germany were used
of non-angiotensin converting enzyme-1 (ACE-I)/non-to approximate the potential cost savings from reduced time
with ESRD and fewer ESRD cases on a EU wide basis. There angiotensin II antagonist (AIIA) conventional antihy-
are approximately 700,000 diagnosed type 2 diabetes patients pertensive therapy in 1513 patients with type 2 diabetes
with proteinuria (urine albumin/creatinine 300 mg/g) in the
and nephropathy. Patients enrolled had type 2 diabetesEU. The addition of losartan to the treatment regimen of these
and a urinary albumin:creatinine ratio of at least 300patients is expected to lead to a reduction of 44,100 cases
of ESRD, 64,400 fewer person-years with ESRD, and reduce mg/g on a first morning specimen. Ninety-seven percent
ESRD-related costs by C 2.6 billion over 3.5 years based on of the patients were either receiving antihypertensiveRENAAL data. Treatment with losartan not only reduced the
therapy or were noted as having had hypertension butincidence of ESRD, but also can result in substantial cost sav-
were not receiving antihypertensive therapy at baseline.ings in the European Union.
Losartan reduced the incidence of doubling of serum
creatinine, end-stage renal disease (ESRD), or death byKey words: type 2 diabetes, losartan, end-stage renal disease, angioten-
sin II antagonist, RENAAL Study. 16% (P  0.022) and reduced the risk of progression to
onset of ESRD defined as the initiation of dialysis or 2002 by the International Society of Nephrology
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Table 1. Population statistics on diabetes in the European Uniontransplantation by 29% (P  0.002). The benefit ex-
and estimated number of diagnosed type 2 diabetic
ceeded that attributable to changes in blood pressure. patients with proteinuria
Reduction of the risk of the progression of type 2
Estimated numberdiabetes with nephropathy to ESRD can have important Population with diagnosed type 2 diabetic
public health implications in the European Union (EU). Country diabetes patients with proteinuria
We set out to quantify the at-risk population in the EU, Austria 372,000 15,256
Belgium 453,000 18,577and to extrapolate the potential effect of losartan on the
Denmark 246,100 10,088burden and costs associated with ESRD in this popula-
Finland 222,000 9,104
tion over 3.5 years. France 2,628,000 107,774
Germany 3,821,000 156,698
Greece NA NA
Ireland 121,000 4,962METHODS
Italy 3,028,000 124,178
The reduction in number of new ESRD cases is calcu- Luxembourg 19,000 779
Netherlands 662,000 27,148lated by combining type 2 diabetes population estimates
Portugal 506,000 20,751for the EU with the percent absolute risk reduction of
Spain 1,945,000 79,764
ESRD observed in RENAAL. In RENAAL the pre-spe- Sweden 472,000 19,357
United Kingdom 2,571,000 105,436cified primary hypothesis for health economic analyses
was that therapy with losartan compared to placebo European Union total 17,066,000 699,873
would reduce the within-trial cumulative ESRD-related
costs after 3.5 years of follow-up; therefore, the primary
results are presented for this time point. The number of
days each patient experienced ESRD was defined as the itoneal dialysis based on utilization patterns for dialysis
length of time from onset of ESRD, defined as initiation services in Germany. On a per-patient basis, applying
of chronic dialysis or renal transplant, until the minimum the cost of ESRD to the days of ESRD avoided (C 111
of death or study end. ESRD person-years free with multiplied by 33.6 days) leads to a C 3,730 savings in
losartan treatment was calculated by multiplying the ESRD-related costs per patient treated over 3.5 years
at-risk population estimate with the per patient ESRD increasing to C 5,206 after four years.
days avoided, and then dividing by the number of days
in a year.
RESULTSThe number of individuals in the EU roughly meeting
We estimate there are approximately 700,000 diag-the entry criteria for RENAAL is estimated from a vari-
nosed patients with type 2 diabetes and proteinuria (urineety of sources. EUROSTAT reports there are 17.1 mil-
albumin/creatinine 300 mg/g) in the EU. The numberlion individuals with diabetes in the EU [7]. The report
of diabetics reported by country within the EU and thedid not provide a breakdown on the distribution of type 1
estimate of diagnosed type 2 diabetic patients with pro-and type 2 diabetes. Therefore, we assumed that 94.9%
teinuria is shown in Table 1.of these patients have type 2 diabetes based on a previous
The cumulative incidence of ESRD for both treatmentstudy reporting on the distribution of type 1 and type 2
groups in RENAAL is shown in Table 2. At 3.5 yearsdiabetes in Europe [2]. We assume that 67% of these
27.1% of the patients treated with conventional hyper-individuals were diagnosed patients based on a report
tensive therapy alone progressed to ESRD compared toof prevalent cases of type 2 diabetes in Europe estimated
20.8% with losartan. The percent absolute risk reductionto be diagnosed in 1999 [8]. We assumed that 6.45% of
with losartan observed in RENAAL was 6.3% (95% CI,these patients have proteinuria (albumin/creatinine ratio
1.7 to 10.9; P  0.007) over 3.5 years increasing to 7.4%300 mg/g) based on an analysis of data from NHANES
after four years (95% CI, 2.2 to 12.6; P  0.005). ThereIII in the United States [9]. We further assumed that
was a mean of 76.1 ESRD days with losartan comparedthese patients would experience events similar to the
with 109.7 ESRD days with placebo over 3.5 years. Com-RENAAL participants.
pared to placebo, losartan reduced the number of daysEnd-stage renal disease costs in 1999 from Germany
with ESRD by 33.6 (95% CI, 10.9 to 56.3; P  0.004)(C 111 per day, or C 40,414 per year) are used to approxi-
per patient at risk over 3.5 years increasing to 46.9 daysmate the potential cost savings from reduced time with
after four years (95% CI, 19.1 to 74.7; P  0.009). TheESRD and fewer ESRD cases on an EU wide basis [10].
cumulative number of days with ESRD is shown in Fig-These costs include specialist dialysis services, medical
ure 1.services, inpatient or outpatient treatment of dialysis
Extrapolating the per-patient results of RENAAL tocomplications, transport, and erythropoietin medication.
the population estimated to be at-risk in the EU, theCosts for ESRD represent a weighted average of costs
for hemodialysis at a center, hospital or at home, and per- addition of losartan to the treatment regimen of these
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Table 2. RENAAL: Within-trial cumulative incidence of ESRD by duration of follow-up
Difference
Follow-up Losartan Placebo (losartan  placebo) 95% CI P value
2.0 years 0.094 0.121 0.026 (0.057, 0.005) 0.102
2.5 years 0.130 0.168 0.037 (0.073, 0.002) 0.041
3.0 years 0.167 0.226 0.059 (0.100, 0.018) 0.005
3.5 years 0.208 0.271 0.063 (0.109, 0.017) 0.007
4.0 years 0.231 0.305 0.074 (0.126, 0.022) 0.005
Table 3. Estimates of potential avoided ESRD cases and
ESRD years over 3.5 years in the European Union
Estimate of potential ESRD
Country Cases avoided Years avoided
Austria 961 1,403
Belgium 1,170 1,709
Denmark 636 928
Finland 574 838
France 6,790 9,914
Germany 9,872 14,415
Greece NA NA
Ireland 313 456
Italy 7,823 11,423
Luxembourg 49 72
Fig. 1. Cumulative number of days with end-stage renal disease (ESRD) Netherlands 1,710 2,497
per patient by duration of follow-up. Symbols are: (dashed line) placebo; Portugal 1,307 1,909
(solid line) losartan. Spain 5,025 7,338
Sweden 1,219 1,781
United Kingdom 6,642 9,699
European Union total 44,092 64,383
(95% Confidence interval) (11,898–76,286) (20,886–107,879)
Fig. 2. Estimated cumulative number of ESRD cases in the European
Union (EU). Symbols are: (dashed line) placebo; (solid line) losartan.
Fig. 3. Estimated cumulative ESRD-related costs in the EU. Symbolspatients was expected to lead to a reduction of 44,100
are: (dashed line) placebo; (solid line) losartan.cases of ESRD (95% CI, 11,898 to 76,286) over 3.5 years
and an increase to 51,800 after four years. Figure 2 shows
the cumulative number of ESRD events over the within
trial period. Additionally, there was an estimated 64,400 The estimated cumulative ESRD-related costs in the
EU over the within trial period is shown in Figure 3.fewer person-years with ESRD (95% CI, 20,886 to 107,879)
over 3.5 years increasing to 89,900 ESRD-free person- Extrapolating the per patient savings in ESRD-related
cost for patients treated with losartan to the target popu-years after four years. An estimate of the potential risk
reduction of new ESRD cases and ESRD-free person- lation in the EU led to a reduction in ESRD-related
costs of C 2,602 million (C 2.6 billion) over 3.5 years,years over 3.5 years by county in the EU is shown in
Table 3. increasing to C 3.6 billion after four years.
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DISCUSSION with losartan is similar to that in the trial. This is not an
unreasonable assumption given that 19% of the patientsThe RENAAL Study showed that in type 2 diabetics
in RENAAL were enrolled in Europe; however, the trialwith nephropathy there is a significant reduction in the
was not powered to address whether this is indeed therisk of progression to ESRD with the angiotensin II an-
case. The 95% confidence intervals shown around thetagonist losartan. The public health implications of this
estimated risk reduction of ESRD cases and ESRD daysfinding are important to the European Union. We estimate
provides some sense of the variability captured in thethat approximately 700,000 individuals roughly meet the
trial for factors such as geographic region.entry criteria for RENAAL in the EU. Extending treat-
To the extent possible we have based our assumptionsment to this population has the potential to avoid 44,100
on population statistics on diabetes related to Europe.cases of ESRD, and to result in 64,400 ESRD-free per-
It is not possible in the context of this report to confirm
son-years over 3.5 years. whether there are: more or less diabetics in the EU than
Reduction of the risk of progression of diabetic ne- is reported in EUROSTAT; differences in distribution of
phropathy to renal disease and failure is a high priority type 1/type 2 diabetes; a greater proportion of diabetics
for many countries within the EU. The prevalence and in- diagnosed; or whether a greater proportion of diagnosed
cidence of type 2 diabetes is growing. Demand on facili- type 2 diabetic have nephropathy. Changes in the assumed
ties and resources directed to providing dialysis and renal variable will obviously increase or decrease the popula-
transplants to the population represented in RENAAL tion basis of our extrapolations. For example, there have
are expected to increase in the future. The European been some reports in Europe that proteinuria in type 2
Renal Registry reports there were 317,131 prevalent diabetics is more prevalent than what has been reported
cases and 63,416 incident cases of patients receiving ei- in the NHANES III statistics. If we double the preva-
ther dialysis or renal transplant in 1996 [11]. This suggests lence of proteinuria from 6.45% to 12.9%, then the at-
that over 3.5 years one might expect 222,000 incident risk population increases from 700,000 to 1,400,000. As
cases of ESRD in Europe if the rate of incident cases a consequence, the estimated risk reduction in ESRD
remained the same as in 1996. The incidence of ESRD, cases increases to 88,200 after 3.5 years. Thus, the esti-
however, continues to increase worldwide. In Germany, mated at-risk population and subsequent estimated risk
for example, the incidence of ESRD attributable to type reduction in ESRD on a population basis may vary if
country-specific and/or other EU-wide data become avail-2 diabetes is expected to increase from 4900 cases in 2000
able and are used in the analysis.to 9500 cases in 2010 [abstract; Liebl et al, Diabetologia
The direct costs of ESRD from Germany were used45(Suppl 2):A301, 2002]. From the perspective of public
to extrapolate to the EU the potential economic benefithealth care systems in the EU, the results of RENAAL
of losartan in reducing the number of days with ESRD.are consistent with the goals of reducing the rate of new
These costs were chosen since they represented the mostcases of end-stage renal disease.
recently published data on the cost of ESRD in EuropeWe estimate that expanded use of losartan in the at-risk
at the time of the analysis. Costs for ESRD are not uni-type 2 diabetic nephropathy population in the EU has
formly available for all countries within the EU. The usethe potential to reduce healthcare expenditures for ESRD
of cost data from Germany provides a conservative basisby C 2.6 billion over 3.5 years. It has been noted that a
for estimating the potential ESRD-related cost savingsconsiderable amount of healthcare funding in Europe is
on an EU-wide basis. By way of comparison, the annualspent on treating dialysis patients [12]. Expenditures for
direct cost of ESRD in various other countries have sinceESRD will likely continue to grow in European countries
been reported to be C 58,800 in France (presentation;as the number of diabetic patients going to renal failure
Hannedouche et al, European Health Economics Societyincreases. In the US, spending on ESRD in 1999 was
Annual Meeting, Paris, July 2002), C 54,000 in Spain (pre-
US$17.9 billion for both Medicare and non-Medicare sentation; Martı´nez-Castelao et al, XXXIII Congreso de
funded care [13]. Medicare funded care alone is pro- la Sociodad Espan˜ola de Nefrologia, Bilbao, October
jected to more than double from US$11.8 billion in 1998 12–16, 2002), C 49,090 in Switzerland [abstract; Sandoz
to US$28.3 billion in 2010 [14]. If spending trends on et al, Diabetologia 45(Suppl 2):A302, 2002], and C 54,300
ESRD in the US are indicative of trends in Europe, then in the United Kingdom (abstract; Weaver et al, J Hum
similar increases in spending of scarce human, facility, Hypertens 16:13A, 2002). Indirect costs due to health-
and economic resources on ESRD will occur. related absenteeism and reduced productivity are not
There are some limitations to analyses extrapolating considered in our estimate of the potential savings in
per patient trial results to an estimated at-risk popula- ESRD-related costs. In Sweden the annual indirect cost
tion. First, there is less certainty about the patient charac- attributed to ESRD can be almost as large as the direct
teristics contained in the population estimates for the costs for ESRD [15]. The ESRD-related costs savings
EU than for the participants in RENAAL. We assume for the EU would be larger if indirect costs were included
in our estimates.that the rate of ESRD in Europe and the resulting benefit
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